- The company is impacted by staffing issues and the pandemic which hamper growth at the moment, but the shares are already at a 52-week low.
- The company remains very interesting because of its proprietary technology and its huge market opportunity.
- It doesn’t look like there are immediate catalysts, but patient capital is likely to be rewarded at these levels.
- Learn More »